Overview

The IRESSA Novel Head and Neck Chemotherapy Evaluation Study

Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the objectie tumour response rate between the cisplatin/5FU and cisplatin/5FU plus ZD1839 combination
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Cisplatin
Gefitinib